Alector, Inc. (NASDAQ:ALEC) Q2 2023 Results Conference Call August 3, 2023 4:30 PM ET
Company Participants
Katie Hogan - Senior Director of Corporate Communication and Investor Relations
Dr. Arnon Rosenthal - Co-Founder and CEO
Dr. Sara Kenkare-Mitra - President and Head of Research and Development
Dr. Gary Romano - Chief Medical Officer
Dr. Marc Grasso - Chief Financial Officer.
Conference Call Participants
Graig Suvannavejh - Mizuho Securities
Paul Matteis - Stifel
Tom Shrader - BTIG
Myles Minter - William Blair
Operator
Good afternoon, ladies and gentlemen, and welcome to the Alector Midyear 2023 Earnings Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded.
I would now like to turn the call over to Katie Hogan, Senior Director of Corporate Communication and Investor Relations. Please go ahead.
Katie Hogan
Thank you, operator, and good afternoon, everyone. Earlier this afternoon we released our financial results for the second quarter 2023. The press release is available on our website at www.alector.com, and our 10-Q was filed with the Securities and Exchange Commission this afternoon. Joining me on the call today are Dr. Arnon Rosenthal, Co-Founder and CEO; Dr. Sara Kenkare-Mitra, President and Head of Research and Development; Dr. Gary Romano, Chief Medical Officer; and Dr. Marc Grasso, Chief Financial Officer.
After our formal remarks, we'll open the call for Q&A. I'd like to note that during this call, we will be making a number of forward-looking statements. Please take a moment to review our slide on the webcast, which contains our forward-looking statement disclosure. And we also encourage you to review our SEC filings for more information.
I would now like to turn the call over to Arnon Rosenthal, Chief Executive Officer. Arnon?
Dr. Arnon Rosenthal
Thank you, Katie, and good afternoon, everyone. We appreciate you joining our conference call today. I'll start by highlighting Alector's key initiatives during the first half of 2023. Next, Sara will show the progress we believe we have achieved with our immuno-neurology research. Then I'll invite Gary to discuss the late-stage clinical program. Afterwards, Marc will provide an update on our financial results and milestone outlook.
Today, Alector is a late-stage clinical biotechnology company with an advanced pipeline that includes novel first-in-class clinical programs. We also have world-class partnerships in which we retain significant price as well as innovative research and technology portfolio. Regarding our INFRONT-2 program, we'll provide more details about our INVOKE-2 Phase II clinical trial with AL002. The trial is approaching full enrollment. And nearly all eligible participants are rolling over into the long-term extension portion of the study. We're also looking forward to sharing key highlights from the 002 program we presented at the Alzheimer's Association International Conference of AAIC in July. As presented at AAIC, in a mouse model of Alzheimer's disease, our antibody AL002C was shown to reduce total tau in the serum, which is a biomarker for neural repair, as well as to increase the ratio of Abeta 42 to 40, which may make remodeling of amyloid plaque.